Margarida Maia, PhD,  science writer—

Taking Orkambi (lumacaftor/ivacaftor) for more than two years helped clear trapped air from the lungs of children with cystic fibrosis (CF), ages 6-11, but didn’t prevent an abnormal widening of the airways, a real-world study finds. The findings indicate the medication may not completely stop lung damage from…

Treatment with Kaftrio, a triple combo of elexacaftor, tezacaftor, and ivacaftor sold as Trikafta in the U.S., may help reduce the number of medications people with cystic fibrosis (CF) take each day, a study found. Patients may have to take multiple medications to manage all symptoms of…

Both genetics and environmental factors, such as attending daycare, family income, and maternal education, may determine how early some lung problems develop in children with cystic fibrosis (CF), a study finds. This is important because while variations in a person’s genes can’t be modified, “some extrinsic exposures can and…

The Cystic Fibrosis (CF) Foundation will put up to $2 million into an effort by Nosis Bio to use artificial intelligence (AI) to design carriers that can safely deliver gene therapy into the lungs of people with CF. “This type of therapy has the potential to treat anyone with…

Undernutrition, or not getting enough nutrients to meet the body’s needs, may occur in as many as half of hospitalized children with cystic fibrosis (CF), making it more common than in other chronic diseases, a study finds. The study, “Undernutrition is still highly frequent in hospitalized children…

More lumps of fat and hardened deposits, called calcifications, may show up on imaging scans of the pancreas of people with cystic fibrosis (CF) who have diabetes, a study shows. These findings suggest doctors can use computed tomography (CT) imaging to help diagnose CF-related diabetes and distinguish these…

Kaftrio, sold as Trikafta in the U.S., continues to thin mucus and to reduce the number of harmful bacteria in the airways when taken for over a year by people with cystic fibrosis (CF), according to an observational study in Germany. While long-term use of Vertex…

Body composition assessments, particularly fat mass and fat-free mass, may be more informative than body mass index (BMI) for monitoring weight gain in cystic fibrosis (CF) patients starting Kaftrio (elexacaftor/tezacaftor/ivacaftor), a Welsh real-world study suggests. The researchers found that while patients’ BMI, a ratio of weight to height, significantly…

First Wave BioPharma has finished dosing in its Phase 2 clinical study, SPAN, in which a new adrulipase formulation is being tested as a potential exocrine pancreatic insufficiency (EPI) treatment in people with cystic fibrosis (CF). With the last patient dosed, the company remains on track for next…

Kaftrio improved lung function for up to 2.5 years in cystic fibrosis (CF) patients with advanced disease who had early access to the medication in Spain, according to a real-world study. Taking Kaftrio, a triple combination of elexacaftor, tezacaftor, and ivacaftor, also reduced the frequency of exacerbations, when…